blinatumomab,brexucabtagene autoleucel,inotuzumab
pfizer,amgen,gilead,ucb pharmaceuticals,astellas
['bet', 'brexu-cel', 'leusm', 'blinatumomab', 'zuma-3', 'inotuzumab']
zuma-3 vs scholar-3 retrospective matching adults with all 25 months brexu-cel vs. 5.5 months soc. outcomes poor regardless of blina/ino exposure in soc and better for car-t. shah 1368 #ash22 #leusm #tcellrx 
Associate Professor @UANL Monterrey, Mexico. Interested in HSCT, acute leukemia in LMIC. ASTCT. LABMT. ASH. AMEH. SMTT. #bmtsm #leusm #mmsm #lymsm #GlobalBMT